Cepheid's Q4 Revenues Jump 36 Percent on Strong Clinical Sales | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Cepheid reported after the close of the market Thursday that its fourth-quarter revenues rose 36 percent on particularly strong clinical systems sales.

The Sunnyvale, Calif.-based molecular diagnostics firm reported total revenues of $80.1 million for the three-month period ended Dec. 31, up from $58.7 million for Q4 2010. Cepheid easily beat analysts' consensus estimate for revenues of $73.7 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.

A cancer researcher retracts 19 articles from one journal for image manipulation, according to Retraction Watch.

Precision medicine has to consider context in addition to genetic mutations in cancer treatment, Medscape reports.

Genomics may help the Cavendish banana from succumbing to fungal infections, a trio of researchers writes at the Conversation.